# Lakewood-Amedex Biotherapeutics Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Lakewood-Amedex Biotherapeutics Inc.). ## Overview Lakewood-Amedex Biotherapeutics Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing locally delivered antimicrobials for infectious diseases. Its lead program is Nu-3, a Bisphosphocin® antibacterial being studied for topical treatment of mildly infected diabetic foot ulcers, alongside earlier-stage pipeline compounds and a patent portfolio covering its technologies. ## Products & services • Nu-3 topical antibacterial for mildly infected diabetic foot ulcers • Bisphosphocin® small-molecule antimicrobial platform • Early-stage antimicrobial pipeline compounds • Patent-protected drug candidates and related technologies - **Lead clinical candidate** (0%) — Nu-3 and related formulations being developed for topical treatment of infected wounds. - **Antimicrobial platform** (0%) — Bisphosphocin®-based small-molecule compounds targeting bacterial infections and AMR. - **Pipeline development** (0%) — Earlier-stage infectious disease programs under preclinical and clinical evaluation. - **Intellectual property** (0%) — Issued patents and pending applications covering products and technologies in major markets. - Nu-3 topical antibacterial for mildly infected diabetic foot ulcers - Bisphosphocin® small-molecule antimicrobial platform - Early-stage antimicrobial pipeline compounds - Patent-protected drug candidates and related technologies ## Customers The company does not yet sell approved products, so its immediate “customers” are not commercial buyers but regulators, clinical investigators, and future healthcare providers that would use its therapies if approved. Its eventual end users are patients with infectious diseases, especially those with diabetic foot ulcers and other bacterial infections where local treatment may be useful. The commercial buyer, if development succeeds, would likely be hospitals, wound-care providers, and other healthcare systems purchasing prescription therapeutics. - **Regulatory authorities** (primary) — FDA and comparable agencies review the clinical package needed to advance Nu-3 and other candidates. - **Clinical trial sites and investigators** (primary) — Hospitals, clinics, and researchers conduct the safety, dose, and efficacy studies required for development. - **Wound-care and hospital buyers** (secondary) — Future commercial buyers for topical anti-infective treatments used in diabetic foot ulcers and similar infections. - **Patients with infectious diseases** (secondary) — End users who would receive locally delivered antimicrobials if the products reach market. - Regulators reviewing clinical and non-clinical data for approval - Clinical investigators running Nu-3 and pipeline studies - Hospitals and wound-care providers as future buyers - Patients with infected wounds and resistant bacterial infections - Healthcare systems seeking topical anti-infective options ## Geography Lakewood-Amedex is headquartered in University Park, Florida and is organized in the United States. Its business is currently centered on U.S.-based research, development, and regulatory activity, while its patent coverage is described as extending into major pharmaceutical markets. Because it has no approved products or product revenue, geography today mainly affects where development work is performed and where future commercialization rights may be pursued. - Headquartered in University Park, Florida, United States - U.S.-based clinical development and corporate operations - Patent coverage extends into major pharmaceutical markets - No product revenue yet, so no commercial geography disclosed ## Strategy The company’s strategy is to advance Nu-3 through clinical development, starting with safety and dose-response work and then moving toward comparative studies needed for later-stage trials. It is also refining earlier pipeline compounds to identify the best indications for non-clinical and clinical evaluation, while relying on its patent estate to support future commercialization options. Success depends on regulatory approval and the ability to fund multi-year development programs. - **Advance Nu-3 through clinical development** (short-term) — Nu-3 is the lead asset and the main path to any future product revenue. - **Refine pipeline indication strategy** (medium-term) — Earlier-stage compounds need clear clinical targets before costly development. - **Protect and monetize intellectual property** (long-term) — Patent coverage supports exclusivity and future partnering or commercialization. - Advance Nu-3 from exploratory trials into Phase 2 studies - Define optimal dose and regimen for topical iDFU treatment - Progress earlier-stage antimicrobial compounds toward indication selection - Use patent protection to support future commercialization - Secure funding to support multi-year clinical development ## Risks The company faces the typical risks of a clinical-stage biotech: development failure, regulatory delay, and uncertainty over whether any candidate will ever reach commercialization. It also depends on external financing to fund operations, and its value is highly sensitive to clinical outcomes, patent protection, and the medical need for new antimicrobials in resistant infections. - **Clinical development failure** [high] — Nu-3 and other candidates must prove safety and efficacy in human studies before commercialization. - **Regulatory approval risk** [high] — Advancement depends on FDA or comparable authorities approving trial results and later marketing applications. - **Financing dependence** [critical] — The company has no product revenue and must fund development through external capital sources. - **Antibiotic resistance and competitive science risk** [medium] — AMR targets are scientifically difficult, and new therapies can be undermined by resistance or better alternatives. - **Intellectual property risk** [medium] — Patent scope, validity, and enforceability are central to future exclusivity and partnering value. - Clinical trials may fail to show safety or efficacy - FDA or other regulators may not approve product candidates - Future funding may be unavailable or too dilutive - Patent protection may not prevent competition or challenges - AMR drug development is scientifically and commercially uncertain ## Accounting As a clinical-stage biotech with no product sales, the company’s accounting is dominated by R&D expense recognition, stock-based compensation, and financing instruments rather than revenue accounting. Investors should also watch estimates around going-concern funding needs, the valuation and conversion of preferred stock and notes, and any future impairment or capitalization judgments tied to development assets and patents. - **Research and development expense timing** — Affects operating loss and comparability across periods - **Stock-based compensation** — Affects operating expenses and dilution analysis - **Convertible notes and preferred stock** — Affects interest expense, equity, and potential dilution - **Going-concern and liquidity estimates** — Affects risk assessment and disclosure emphasis - No product revenue yet, so results are driven by operating expenses - R&D spending is expensed as incurred and can fluctuate by trial timing - G&A includes public company costs and stock-based compensation - Convertible notes and preferred stock require careful valuation and conversion accounting - Going-concern and liquidity assumptions affect financial statement presentation --- *Last updated: 2026-06-16T23:00:36.457936+00:00*